Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial

被引：2

作者：

Proto, C. ^{[1
]}

Manglaviti, S. ^{[1
]}

Galli, G. ^{[1
]}

Imbimbo, M. ^{[2
]}

Alvisi, M. F. ^{[3
]}

Zollo, F. ^{[3
]}

Perrino, M. R. A. ^{[4
]}

Giuliano, M. ^{[5
]}

Pietroluongo, E. ^{[5
]}

Ballatore, Z. ^{[6
]}

Chella, A. ^{[7
]}

Fabbri, A. ^{[8
]}

Vigorito, R. ^{[9
]}

De Braud, F. G. M. ^{[10
]}

Pasello, G. ^{[11
,12
,14
]}

Petrini, I. ^{[13
]}

Berardi, R.

Zucali, P. A.

Ganzinelli, M.

Garassino, M. C. ^{[15
]}

Lo Russo, G.

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[2] CHUV Ctr Hosp Univ Vaudois, Dept Oncol, Fdn IRCCS Ist Nazl Tumori, Lausanne, Switzerland

[3] Ist Ric Farmacol Mario Negri IRCCS, Methodol Clin Res Lab, Milan, Italy

[4] IRCCS Humanitas Res Hosp, Dept Oncol, Rozzano, Italy

[5] AOU Federico II, Dept Clin Med & Surg, Naples, Italy

[6] AOU Marche, Clin Oncolog, Torrette di Ancona, Italy

[7] AOU Pisana Stabilimento Santa Chiara, Traslat Res & New Technol Med, Pisa, Italy

[8] Fdn IRCCS Ist Nazl Tumori, Pathol & Lab Dept, Milan, Italy

[9] Fdn IRCCS Ist Nazl Tumori, Dept Intervent Radiol, Milan, Italy

[10] Univ Milan, Med Oncol & Hematol Dept, Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[11] Univ Padua, Dept Surg Oncol & Gastroenterol, Med Sch, Padua, Italy

[12] Veneto Inst Oncol IOV IRCCS, Med Oncol 2, Padua, Italy

[13] AOU Pisana Stabilimento Santa Chiara, Traslat Res & New Technol Med, Pisa, Italy

[14] Univ Politecn Marche, Clin Oncol, AOU Marche, Ancona, Italy

[15] Univ Chicago, Hematol Oncol Sect, Dept Med, Fdn IRCCS Ist Nazl Tumori, Chicago, IL USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.101

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA98

引用

页码：S1337 / S1337

页数：1

共 50 条

[1] Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)
Proto, C.
Ganzinelli, M.
Manglaviti, S.
Imbimbo, M.
Galli, G.
Marabese, M.
Zollo, F.
Alvisi, M. F.
Perrino, M.
Cordua, N.
Borea, F.
de Vincenzo, F.
Chella, A.
Cappelli, S.
Pardini, E.
Ballatore, Z.
Lucarelli, A.
Ambrosini, E.
Giuliano, M.
Pietroluongo, E.
Mulargiu, C.
Fabbri, A.
Prelaj, A.
Occhipinti, M.
Brambilla, M.
Mazzeo, L.
Beninato, T.
Vigorito, R.
Ruggirello, M.
Greco, F. G.
Calareso, G.
Miliziano, D.
Rulli, E.
De Simone, I.
Torri, V.
de Braud, F. G. M.
Pasello, G.
De Placido, P.
Berardi, R.
Petrini, I.
Zucali, P.
Garassino, M. C.
Lo Russo, G.
ANNALS OF ONCOLOGY, 2024, 35 (09) : 817 - 826
[2] RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma
Imbimbo, Martina
Vitali, Milena
Fabbri, Alessandra
Ottaviano, Margaret
Pasello, Giulia
Petrini, Iacopo
Palmieri, Giovannella
Berardi, Rossana
Zucali, Paolo
Ganzinelli, Monica
Marabese, Mirko
Broggini, Massimo
Marino, Mirella
Trama, Annalisa
Rulli, Eliana
Hollander, Lital
Pruneri, Giancarlo
Torri, Valter
Garassino, Marina Chiara
CLINICAL LUNG CANCER, 2018, 19 (05) : E811 - E814
[3] Phase II trial of atezolizumab plus carboplatin and paclitaxel in patients with metastatic or recurrent thymic carcinoma: Marble study
Mimori, T.
Shukuya, T.
Goto, Y.
Asao, T.
Takayama, K.
Kaira, K.
Tanaka, H.
Ko, R.
Tsubata, Y.
Tachihara, M.
Suzuki, T.
Tanizaki, J.
Sugawara, S.
Zenke, Y.
Shirai, Y.
Hayashi, T.
Mori, K.
Takahashi, K.
ANNALS OF ONCOLOGY, 2024, 35 : S1631 - S1632
[4] S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma.
Tsao, Anne S.
Hsieh, Ming-Hui
Koczywas, Marianna
Tu, Janet Chen
Riess, Jonathan W.
Tanvetyanon, Tawee
Ma, Barbara Ting-Wen
Zhao, Yingqi
Redman, Mary Weber
Edelman, Martin Joseph
Gandara, David R.
Kelly, Karen
Gray, Jhanelle E.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Tsao, Anne S.
Hsieh, Ming-Hui
Koczywas, Marianna
Tu, Janet
Riess, Jonathan
Tanvetyanon, Tawee
Ma, Barbara T.
Zhao, Ying-Qi
Redman, Mary W.
Edelman, Martin J.
Gandara, David R.
Gray, Jhanelle E.
Kelly, Karen L.
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (12):
[6] Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma
Tan, EH
Khoo, KS
Wee, J
Fong, KW
Lee, KS
Lee, KM
Chua, ET
Tan, T
Khoo-Tan, HS
Yang, TL
Au, E
Tao, M
Ong, YK
Chua, EJ
ANNALS OF ONCOLOGY, 1999, 10 (02) : 235 - 237
[7] Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma
Lemma, Girum L.
Lee, Ju-Whei
Aisner, Seena C.
Langer, Corey J.
Tester, William J.
Johnson, David H.
Loehrer, Patrick J., Sr.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) : 2060 - 2065
[8] Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
Johnson, DH
Fehrenbacher, L
Novotny, WF
Herbst, RS
Nemunaitis, JJ
Jablons, DM
Langer, CJ
DeVore, RF
Gaudreault, J
Damico, LA
Holmgren, E
Kabbinavar, F
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) : 2184 - 2191
[9] Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma
Igawa, Satoshi
Murakami, Haruyasu
Takahashi, Toshiaki
Nakamura, Yukiko
Tsuya, Asuka
Naito, Tateaki
Kaira, Kyoichi
Ono, Akira
Shukuya, Takehito
Tamiya, Akihiro
Endo, Masahiro
Yamamoto, Nobuyuki
LUNG CANCER, 2010, 67 (02) : 194 - 197
[10] Weekly, paclitaxel plus carboplatin in patients with metastatic transitional cell carcinoma of the urothelium who failed MVAC: Phase II trial
Kouno, T.
Ando, M.
Yonemori, K.
Matsumoto, K.
Komiyama, M.
Okajima, E.
Matsuoka, N.
Fujimoto, H.
Fujiwara, Y.
EJC SUPPLEMENTS, 2005, 3 (02): : 246 - 247

← 1 2 3 4 5 →